Constellation Pharmaceuticals (Constellation Pharmaceuticals) PB Ratio : 4.32 (As of May. 12, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-12), Constellation Pharmaceuticals's share price is $33.99. Constellation Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2021 was $7.88. Hence, Constellation Pharmaceuticals's PB Ratio of today is 4.32.

The historical rank and industry rank for Constellation Pharmaceuticals's PB Ratio or its related term are showing as below:

CNST' s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.32
Current: 4.32

During the past 5 years, Constellation Pharmaceuticals's highest PB Ratio was 4.32. The lowest was 0.00. And the median was 0.00.

CNST's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs CNST: 4.32

During the past 12 months, Constellation Pharmaceuticals's average Book Value Per Share Growth Rate was 4.40% per year.

Back to Basics: PB Ratio

Constellation Pharmaceuticals PB Ratio Historical Data

The historical data trend for Constellation Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals PB Ratio Chart

Constellation Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

PB Ratio

0.99

5.82

3.35

Constellation Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
PB Ratio	Get a 7-Day Free Trial													4.17	3.02	2.18	3.35	2.97

Competitive Comparison of Constellation Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Constellation Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Constellation Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's PB Ratio falls into.

Constellation Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Constellation Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Mar. 2021)
	=	33.99	/	7.875
	=	4.32

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Constellation Pharmaceuticals (NAS:CNST) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Constellation Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 First Street, Suite 200, Cambridge, MA, USA, 02142

Website

http://www.constellationpharma.com

Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

Executives

Emma Reeve	officer: Chief Financial Officer	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine	officer: See Remarks	C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith	director, 10 percent owner	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey	officer: Chief Medical Officer	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu	director	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia	director	215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha	director, officer: See Remarks	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer	officer: Chief Scientific Officer	215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158